Helene Parise (Hélène Parisé)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Diffuse Large B Cell Lymphoma

Replacement Therapy

Top Venues

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Jesse Fishman, Yestle Kim, Helene Parise, Eric M Bercaw, Zachary Smith
Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Journal of medical economics 27 (1) (2024)
Jesse Fishman, Yestle Kim, Helene Parise, Eric M Bercaw, Zachary Smith
Budget impact of resmetirom for the treatment of adults with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). Journal of medical economics (2024)
Matthew Matasar, Javier Sanchez Alvarez, Helene Parise, Eric Zuk, Danilo Di Maio, Sheila Shapouri, Eunice Kim, Shih-Wen Lin
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States. Journal of medical economics 27 (1) (2024)
Matthew Matasar, Javier Sanchez Alvarez, Helene Parise, Eric Zuk, Danilo Di Maio, Sheila Shapouri, Eunice Kim, Shih-Wen Lin
Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States. Journal of medical economics (2024)